Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals M & A Business Strategies

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

  • News

Executive Summary

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

You may also be interested in...



Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.

ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates

ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment. 

Novartis Expands BeiGene Tie-Up To TIGIT Inhibitor In $1bn-Plus Option Deal

Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Deals M & A Business Strategies
Latest Headlines

Jardiance Improves Double-Digit Growth Potential With US Approval In CKD

Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

Two LEAPs Behind: Merck/Eisai Post Pair Of Failures Of Keytruda/Lenvima Combo

Deal Watch: Merck KGAA Teams With AI Biotechs On Drug Discovery Efforts

See All
UsernamePublicRestriction

Register

SC144820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By